ICM
XBI icon

Ionic Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ionic Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$2.4M – 172
2018
Q3 		$2.4M Hold
25,000
– – 0.21% 57
2018
Q2 		$2.38M Buy
+25,000
New +$2.3M 0.14% 95

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Ionic Capital Management's XBI Position: Q4 2024 in Review

Ionic Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 9,650 shares — an estimated $953K sold.

Ionic Capital Management first reported a position in XBI in Q4 2016 and held it in 16 quarters. The position peaked at $2.31M in Q2 2017. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Ionic Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Ionic Capital Management sold 9,650 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $953K.
  • Ionic Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 16 quarters.
  • Ionic Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.31M in Q2 2017.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Ionic Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.